Summary
The epidemiology of COVID-19 is rapidly evolving and a number of companies have begun to invest in this space. The absence of proven therapeutic options and the lack of a vaccine to protect against infection has led to a race to develop effective interventions. A range of players - from pharma and biotech firms to academic institutions and government agencies - have thrown their hats in the ring.
Scope
- - Global epidemiology metrics and trends
- - Snapshot of epidemiological trends to date in the top three most-affected countries
- - An overview of the pipeline for antivirals and vaccines
- - Summary of available efficacy data
- - An assessment of the clinical trials landscape by phase, sponsor type, geography, and other key attributes
- - Highlights in deal-making trends, particularly public-private partnerships
- - Spotlight on social media coverage
Reasons to Buy
- - Global epidemiology metrics and trends
- - Snapshot of epidemiological trends to date in the top three most-affected countries
- - An overview of the pipeline for antivirals and vaccines
- - Summary of available efficacy data
- - An assessment of the clinical trials landscape by phase, sponsor type, geography, and other key attributes
- - Highlights in deal-making trends, particularly public-private partnerships
- - Spotlight on social media coverage
Table of content
Table of Contents
1 Executive Summary
1.1 Report Scope
1.2 Navigate the COVID-19 Outbreak with GlobalData Pharma’s COVID-19 Dashboard
1.3 Monitor the COVID-19 Outbreak with GlobalData Epidemiology Indicators
2 Epidemiology
2.1 Epidemiology: Snapshot as of March 25, 2020
2.2 Epidemiology: Disease Trajectory as of March 25, 2020
2.3 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in China as of March 25, 2020
2.4 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in Italy as of March 25, 2020
2.5 Epidemiology Indicators in the Top 3 Most-Affected Countries: Disease Trajectory in the US as of March 25, 2020
2.6 Epidemiology Forecast: United States
3 Pipeline Overview
3.1 Pipeline Therapeutics: Breakdown by Phase
3.2 Pipeline Therapeutics: Breakdown by Molecule Type
3.3 Pipeline Therapeutics: Breakdown by Type of Developer
3.4 Pipeline Therapeutics: Clinical-Stage Candidates (Phase I - III)
3.5 Pipeline Therapeutics: Preclinical-Stage Candidates
3.6 Pipeline Therapeutics: Currently Available Data
3.7 Pipeline Vaccines: Breakdown by Phase
3.8 Pipeline Vaccines: Breakdown by Developer Type
3.9 Pipeline Vaccines: Clinical and Preclinical-Stage Candidates
4 Pipeline Overview
4.1 Pipeline Therapeutics: Breakdown by Phase
4.2 Pipeline Therapeutics: Breakdown by Molecule Type
4.3 Pipeline Therapeutics: Breakdown by Type of Developer
4.4 Pipeline Therapeutics: Clinical-Stage Candidates (Phase I - III)
4.5 Pipeline Therap
CONTACT US:
North Main Road Koregaon Park, Pune, India - 411001.
International: +1(646)-781-7170
Asia: +91 9169162030
Email: [email protected]
The global rare disease genetic testing market size is expected to reach USD 1.8 Billion by 2027 according to a new study by Polaris Market Research.
The report “Rare Disease Genetic Testing Market Share, Size, Trends, Industry Analysis Report, By Disease Type (Neurological Disorders, Immunological Disorders, Hematology Ailments, Endocrine & Metabolism Disorders, Cancer, Musculoskeletal Disorders, Cardiovascular Disorders, Dermatology Disorders, Others); By Technology; By Specialty; By End-Use; By Regions; Segment Forecast, 2020 – 2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The growing need for on-time diagnosis of uncommon disorders, rising prevalence of rare disorders, innovations in genomic testing, and the focused approach of the market player’s in cost-effective treatments are the key factors responsible for market growth.
Moreover, government-sponsored schemes are also expected to positively impact the market.
In February 2020, the government of India announced financial assistance of INR 15 lacs to the patients suffering from uncommon ailments under the Rashtriya Arogaya Nidhi scheme for a one-time treatment.
The global rare disease genetic testing industry is fragmented based on disease type, technology, specialty, end-use, and region.
`There is emerging information regarding risk factors & some non-modifiable such as age, ethnicity and male gender.
However, in terms of modifiable risk factors, obesity, cardiovascular disease, diabetes, hypertension and lung disease infer an increased risk.
They also plant the flowers and trees in the yard these flowers enhance the beauty of the yard.
Today in this blog, we will discuss about that all services that are provided by the landscaping companies to their clients or customer.
Fertilization is very important if you want to grow your grass perfectly.
Leaf removal- Landscaping companies also provide the services related to the leaf removal, they remove those leaves that are damaged.
Planting more flowers or trees- Landscaping companies also plant more flowers in the yard which every person want from the landscaping company.
With these flowers yard look more beautiful and colorful.
